A Randomized Double-Blind Placebo Controlled Multicenter Trial of Abagovomab Maintenance Therapy in Patients with Epithelial Ovarian Cancer after Complete Response to First Line Chemotherapy
Study on Investigational Treatment for Diabetes
Not Recruiting
100 years or below
Female
Phase
N/A
1 Location
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Breast Cancer
Age:
100 years or below
Gender: Female
Who can participate: Adults aged 18 to 65 with a confirmed diagnosis of diabetes and who are currently managing their condition with medication are eligible to participate.
Study details: Participants will be randomly assigned to receive either the investigational treatment or a placebo. The placebo is an inactive substance designed to mimic the investigational treatment without its therapeutic effects. Participants will attend regular clinic visits for monitoring and assessments.
Updated on
19 Feb 2024.
Study ID: 0701-04 (1010002661)
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
